ストックスクリーナーアプリを入手
34.53
1.26%
0.38
前日終値:
$34.15
開ける：
$34.95
24時間の取引高:
390.12K
Relative Volume:
0.23
時価総額：
$7.09B
収益：
-
当期純損益:
$-464.20M
株価収益率:
-12.87
EPS:
-2.6823
ネットキャッシュフロー:
$-423.09M
1週間 パフォーマンス:
+31.53%
1か月 パフォーマンス:
+20.99%
6か月 パフォーマンス:
+45.91%
1年 パフォーマンス:
+139.14%
1日の値動き範囲:
$33.62
$35.46
1週間の範囲:
$30.10
$36.28
52週間の値動き範囲:
$13.79
$36.28
Immunovant Inc Stock (IMVT) Company Profile
Compare IMVT vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IMVT
Immunovant Inc
|
34.53 | 7.01B | 0 | -464.20M | -423.09M | -2.6823 |
VRTX
Vertex Pharmaceuticals Inc
|
437.38 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
639.83 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
806.50 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.76 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.72 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immunovant Inc Stock (IMVT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-20 | 開始されました | Bernstein | Mkt Perform |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-10-14 | 開始されました | Truist | Hold |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-03-03 | 開始されました | Jefferies | Hold |
| 2025-01-03 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-10-09 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-28 | 開始されました | Oppenheimer | Outperform |
| 2024-03-13 | 開始されました | Goldman | Buy |
| 2024-02-20 | 開始されました | JP Morgan | Overweight |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-13 | アップグレード | UBS | Neutral → Buy |
| 2023-09-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-05-01 | 開始されました | BofA Securities | Buy |
| 2023-04-25 | 開始されました | Citigroup | Buy |
| 2023-03-31 | 開始されました | Piper Sandler | Overweight |
| 2023-03-30 | 開始されました | Stifel | Buy |
| 2023-02-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-01-03 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2022-09-26 | ダウングレード | UBS | Buy → Neutral |
| 2021-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2021-08-03 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2021-08-02 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2021-06-01 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-06-01 | ダウングレード | Stifel | Buy → Hold |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-10-12 | 開始されました | Guggenheim | Buy |
| 2020-10-08 | 開始されました | Stifel | Buy |
| 2020-10-02 | 開始されました | Credit Suisse | Outperform |
| 2020-08-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-02-24 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Immunovant Inc (IMVT) 最新ニュース
CrowdStrike To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Nvidia, Astera Labs, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More Movers - Barron's
IMVT rockets 35% despite wider loss as arthritis drug shines in study - MSN
Stifel Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $49 - Moomoo
Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT) - Seeking Alpha
(IMVT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
IMVT's Q4 loss wider than expected, stock up 35% on strong study data - MSN
Immunovant (IMVT) Is Up 24.2% After Axing Batoclimab To Back IMVT-1402 Autoimmune PivotHas The Bull Case Changed? - simplywall.st
symbol__ Stock Quote Price and Forecast - CNN
Immunovant COO Gloria Melanie sells $101,072 in company stock - Investing.com
Immunovant COO Gloria Melanie sells $101,072 in company stock By Investing.com - Investing.com South Africa
[Form 4] Immunovant, Inc. Insider Trading Activity - Stock Titan
Wells Fargo Sticks to Its Buy Rating for Immunovant (IMVT) - The Globe and Mail
These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Sahm
BofA Securities Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $43 - Moomoo
Immunovant’s Talent Crunch: How Human Capital Risks Could Derail IMVT-1402 Development Across Six Indications - TipRanks
Immunovant (IMVT) Is Up 17.9% After Refocusing On IMVT-1402 Amid Wider LossesHas The Bull Case Changed? - Yahoo Finance
Immunovant director Atul Pande sells $192,000 in shares By Investing.com - Investing.com Nigeria
IMVT Maintains Buy Rating by B of A Securities -- Price Target R - GuruFocus
IMVT Maintains by HC Wainwright & Co. -- Price Target Raised to $40 - GuruFocus
Immunovant (IMVT) Stock Shot up after a Poor Quarterly Showing - FXLeaders
Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV) - Seeking Alpha
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Raises Target Price to $45 - Moomoo
IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data - The Globe and Mail
BofA raises Immunovant stock price target on higher peak sales outlook - Investing.com
A Quick Look at Today's Ratings for Immunovant(IMVT.US), With a Forecast Between $40 to $45 - Moomoo
Immunovant director Atul Pande sells $192,000 in shares - Investing.com India
Immunovant (IMVT) Hits 5-Year High on Stellar Arthritis Treatment Trial - Insider Monkey
Immunovant (IMVT) director exercises options, sells 6,000 shares under 10b5-1 plan - Stock Titan
Immunovant, Inc. Stock 12‑Month Price Target Raised to $43.67, Implies 66% Upside - TradingView
Immunovant Stock Surges 35% After Arthritis Drug Data: Why Wall Street Is Repricing IMVT - TechStock²
Roivant/Immunovant Find Success In Tough-To-Treat RA, Where J&J Failed - Citeline News & Insights
IMVT Stock Jumps As Traders Track Insider Ownership Filing - timothysykes.com
Immunovant rises on IMVT-1402 data in difficult-to-treat RA - BioWorld News
2 Biotech Stocks Are Surging Today Thanks to This Arthritis Drug - Barron's
[144] Immunovant, Inc. SEC Filing - Stock Titan
Immunovant Shares Just Surged 35% – Here’s Why - AskTraders
Immunovant stock hits 52-week high at 30.27 USD By Investing.com - Investing.com Australia
Immunovant, Inc. Stock 12‑Month Price Target Raised to $43.08, Implies 64% Upside - TradingView
Immunovant (IMVT) Stock Soars Over 20% Following Breakthrough Rheumatoid Arthritis Data - MEXC
Stifel reiterates Immunovant stock rating on trial results - Investing.com
Immunovant Stock Surges Despite Disappointing Earnings Miss - Benzinga
Stifel reiterates Immunovant stock rating on trial results By Investing.com - Investing.com Australia
Immunovant, Inc. Stock 12‑Month Price Target Raised to $42.55, Implies 62% Upside - TradingView
Crude Oil Down 5%; Lowe's Posts Upbeat EarningsImmunovant (NASDAQ:IMVT), Lowe's Companies (NYSE:LOW) - Benzinga
Immunovant (IMVT) Stock Surges 22% on Positive Rheumatoid Arthritis Trial Data - MEXC
These Stocks Are Today's Movers: Nvidia, Micron, Intel, United, Hasbro, Toll, Immunovant, Analog Devices, and More -- Barrons.com - Moomoo
Immunovant Inc (IMVT) 財務データ
収益
当期純利益
現金流量
EPS
Immunovant Inc (IMVT) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Pande Atul | Director |
May 20 '26 |
Option Exercise |
8.43 |
6,000 |
50,580 |
122,731 |
| Pande Atul | Director |
May 20 '26 |
Sale |
32.00 |
6,000 |
192,000 |
116,731 |
2.25%
0.46%
大文字化:
|
ボリューム (24 時間):